Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Preston C. Sprenkle, MD

Associate Professor of Urology; Co-Chair, Cancer Liaison Committee, Oncology; Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection; Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology; Director, Urology Research Fellowship, Urology; Director, Urologic Oncology Clinical Fellowship Program, Urology

Contact Information

Preston C. Sprenkle, MD

Mailing Address

  • Urology

    PO Box 208058

    New Haven, CT 06520-8058

    United States

Download CV

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Integration of prostate imaging and genomics for more personalized diagnosis and treatment of prostate cancers. collaborate with translational scientists and machine learning specialists to develop predictive models utilizing multiple clinical factors to improve diagnostic predictions and modeling.

Extensive Research Description

Improving accuracy of prostate cancer diagnosis, staging, and treatment through enhanced imaging techniques with Prostate MRI and targeted prostate biopsies using our clinical outcomes database.

Clinical trial interventions on patients with high risk prostate cancer as well as utilizing new techniques and technologies for ablation (destruction) of prostate cancer using such technologies as cryoablation, irreversible electroporation, TULSA, laser ablation, and others.

Coauthors

Research Interests

Magnetic Resonance Imaging; Prostatectomy; Urology; Genomics; Ablation Techniques; High-Intensity Focused Ultrasound Ablation; Machine Learning

Selected Publications

  • Abstract No. 160 MR Susceptibility-Weighted Imaging During Transurethral Prostate Sono-Ablation Procedures for Guidance of Device Placement to Counter Effect of Intra-Prostatic CalcificationsLee J, Ghanouni P, Costa D, Shin C, Khalighinejad P, Sprenkle P, Staruch R, Beserra A, Arora S. Abstract No. 160 MR Susceptibility-Weighted Imaging During Transurethral Prostate Sono-Ablation Procedures for Guidance of Device Placement to Counter Effect of Intra-Prostatic Calcifications Journal Of Vascular And Interventional Radiology 2023, 34: s74-s75. DOI: 10.1016/j.jvir.2022.12.214.
  • Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.
  • Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesionsFang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.
  • Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancerLokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.
  • PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIESKhajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES Investigative Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
  • MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMYKhajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY Investigative Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
  • PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONSFang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS Investigative Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.
  • MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENINGLeapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING Investigative Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
  • Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
  • Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate CancerBuck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer Urology Practice 2021, 9: 141-149. DOI: 10.1097/upj.0000000000000290.
  • MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONSFang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000001972.05.
  • MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSYKhajir G, Olawoyin O, Leapman M, Sprenkle P. MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSY Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002023.14.
  • Benign and Malignant Diseases of the ProstateSyed J, Sprenkle P. Benign and Malignant Diseases of the Prostate 2020, 651-682. DOI: 10.1007/978-3-319-47771-8_79.
  • PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomyAbello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
  • MP23-11 PREDICTION OF ADVERSE OUTCOMES AT RADICAL PROSTATECTOMY IN GRADE GROUP 2 AND 3 PROSTATE BIOPSIES USING MACHINE LEARNINGPaulson* N, Zeevi T, Papademetris M, Onofrey J, Sprenkle P, Humphrey P, Staib L, Levi A. MP23-11 PREDICTION OF ADVERSE OUTCOMES AT RADICAL PROSTATECTOMY IN GRADE GROUP 2 AND 3 PROSTATE BIOPSIES USING MACHINE LEARNING Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000856.011.
  • MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMYAbello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY Investigative Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
  • PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIALSprenkle* P, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.
  • Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
  • Benign and Malignant Diseases of the ProstateSyed J, Sprenkle P. Benign and Malignant Diseases of the Prostate 2019, 1-32. DOI: 10.1007/978-3-319-20317-1_79-1.
  • P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate CancerYang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
  • PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2 Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.
  • FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSEAmirkhiz* K, Goland-Van Ryn M, Motamedinia P, Leapman M, Sprenkle P, Weiss R. FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSE Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555417.67392.ee.
  • PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCERAbello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
  • PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDERJavier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
  • MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMYAmirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY Investigative Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
  • MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY?Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Investigative Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
  • MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCEHsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE Investigative Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
  • MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MENWang N, Fan R, Sprenkle P, Sonn G. MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN Investigative Urology 2018, 199: e1035. DOI: 10.1016/j.juro.2018.02.2607.
  • MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCELeung C, Syed J, Pan S, Neville T, Sprenkle P. MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCE Investigative Urology 2018, 199: e11. DOI: 10.1016/j.juro.2018.02.126.
  • Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
  • How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
  • Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?Ghabili K, Ghabili K, Swallow M, Swallow M, Suarez-Sarmiento A, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
  • Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.
  • The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men.Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.
  • Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case reportNguyen K, Nawaf C, Levi A, Huber S, Lu A, Say R, Sprenkle P. Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case report Journal Of Clinical Urology 2016, 10: 280-282. DOI: 10.1177/2051415816651561.
  • PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS?Lu A, Lu A, Nawaf C, Rosoff J, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Investigative Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.
  • MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCERNawaf C, Rosoff J, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER Investigative Urology 2016, 195: e158. DOI: 10.1016/j.juro.2016.02.2541.
  • Decision forests for learning prostate cancer probability maps from multiparametric MRIEhrenberg H, Cornfeld D, Nawaf C, Sprenkle P, Duncan J. Decision forests for learning prostate cancer probability maps from multiparametric MRI Proceedings Of SPIE 2016, 9785: 97851j-97851j-14. DOI: 10.1117/12.2216904.
  • MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.Nawaf C, Rosoff J, Rosoff J, Weinreb J, Lu A, Lu A, Levi A, Humphrey P, Schulam P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.
  • MRI-US fusion targeted biopsy results in men with a history of prior cancer.Nawaf C, Rosoff J, Rosoff J, Lu A, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.
  • MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.Nawaf C, Lu A, Lu A, Rosoff J, Rosoff J, Weinreb J, Schulam P, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.
  • Prostate cancer detection rates of negative MP-MRIs.Lu A, Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.
  • MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALEKardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE Investigative Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.
  • MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSYKarnes R, Loeb S, Sprenkle P, Morrell C, MacKintosh F, Rawson L, Neville T. MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSY Investigative Urology 2015, 193: e1078-e1079. DOI: 10.1016/j.juro.2015.02.1917.
  • Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.
  • Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship?Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Benson M, Rutman M. Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship? Journal Of Medicine And The Person 2011, 9: 116-122. DOI: 10.1007/s12682-011-0101-y.
  • 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHESSprenkle P, Sankin A, Savage C, Musser J, Touijer K, Russo P, Coleman J. 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHES Investigative Urology 2011, 185: e507. DOI: 10.1016/j.juro.2011.02.954.
  • COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIESHruby G, Sprenkle P, Lehman D, Durak E, Marruffo F, Mirabile G, McKiernan J, Gupta M, Landman J. COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIES Investigative Urology 2008, 179: 248. DOI: 10.1016/s0022-5347(08)60716-8.
  • THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATIONSprenkle P, Mirabile G, Hruby G, Phillips C, Xavier K, Gupta M, Landman J. THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATION Investigative Urology 2008, 179: 243-244. DOI: 10.1016/s0022-5347(08)60703-x.
  • High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomyPierorazio P, Lambert S, Matsukhani M, Sprenkle P, McCann T, Katz A, Olsson C, Benson M, McKiernan J. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy BJU International 2007, 0: 070907021207002-???. DOI: 10.1111/j.1464-410x.2007.07115.x.
  • Benign prostate hyperplasia in the older maleSprenkle P, Lowe F. Benign prostate hyperplasia in the older male Aging Health 2007, 3: 177-189. DOI: 10.2217/1745509x.3.2.177.
  • 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral MaturationLambert S, Batourina E, Tsai S, Viana R, Sprenkle P, Dutta S, Hensle T, Mendelsohn C. 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral Maturation Investigative Urology 2006, 175: 187-188. DOI: 10.1016/s0022-5347(18)32824-6.
  • 1717: The Bladder Trigone is not a Wolffian Duct RemnantSprenkle P, Batourina E, Tsai S, Lambert S, Paragas N, Glassberg K, Hensle T, Mendelsohn C. 1717: The Bladder Trigone is not a Wolffian Duct Remnant Investigative Urology 2004, 171: 454. DOI: 10.1016/s0022-5347(18)38909-2.

Clinical Trials

ConditionsStudy Title
ProstateA Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
ProstateRandomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
Other Male Genital; ProstateCustomized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)
ProstateSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
ProstateEvaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
ProstatePhase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
ProstateMR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
ProstateActive Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
ProstateA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Edit Profile